← Back to Clinical Trials
Recruiting NCT06490211

NCT06490211 The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06490211
Status Recruiting
Phase
Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Condition Urinary System Carcinoma
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-11-20
Primary Completion 2026-11-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-11-20 with a primary completion date of 2026-11-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Obtain puncture or surgically removed tumor tissue samples from patients with urinary tract tumors and perform RNA-sequencing, Single-cell RNA-sequence, Spatial Transcriptomics, Proteomics, and Intratumoral Microbiome.

Eligibility Criteria

Inclusion Criteria: 1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026; 2. Aged \> 18 years old; 3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion Criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignant tumor other than urinary tract tumor; 4. Unclear pathological diagnosis

Contact & Investigator

Central Contact

Lian Yang

✉ yanglian@hust.edu.cn

📞 18986273791

Frequently Asked Questions

Who can join the NCT06490211 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Urinary System Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06490211 currently recruiting?

Yes, NCT06490211 is actively recruiting participants. Contact the research team at yanglian@hust.edu.cn for enrollment information.

Where is the NCT06490211 trial being conducted?

This trial is being conducted at Wuhan, China.

Who is sponsoring the NCT06490211 clinical trial?

NCT06490211 is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology